CN105688203A - Preparation and use method of duck tembusu virus inactivated vaccine - Google Patents

Preparation and use method of duck tembusu virus inactivated vaccine Download PDF

Info

Publication number
CN105688203A
CN105688203A CN201610164617.6A CN201610164617A CN105688203A CN 105688203 A CN105688203 A CN 105688203A CN 201610164617 A CN201610164617 A CN 201610164617A CN 105688203 A CN105688203 A CN 105688203A
Authority
CN
China
Prior art keywords
duck
tembusu virus
preparation
vaccine
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610164617.6A
Other languages
Chinese (zh)
Inventor
魏思远
赵光伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing Sanjie Zhongxin Bioengineering Co Ltd
Original Assignee
Chongqing Sanjie Zhongxin Bioengineering Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Sanjie Zhongxin Bioengineering Co Ltd filed Critical Chongqing Sanjie Zhongxin Bioengineering Co Ltd
Priority to CN201610164617.6A priority Critical patent/CN105688203A/en
Publication of CN105688203A publication Critical patent/CN105688203A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention discloses a preparation and use method of a duck tembusu virus inactivated vaccine, and relates to the field of a vaccine. The scheme is provided by aiming at the problem that in the prior art, the duck tembusu virus cannot be effectively prevented and treated. The method mainly comprises the steps of virus inoculation, antigen preparation, antigen identification, vaccine preparation and vaccine quality standard and use method, so that the function of preventing the duck tembusu virus is realized.

Description

The method of preparation and use of duck tembusu virus inactivated vaccine
Technical field
The present invention relates to the method for preparation and use of a kind of duck tembusu virus inactivated vaccine, relate generally to vaccines arts。
Background technology
Since 2010, the Some Domestic area popular one of duck with clinical symptoms be foot paralysis, feed intake decline, draw yellow green loose stool, lay eggs rapid drawdown and nervous symptoms, cut open the disease that inspection symptom is that myocardial necrosis, liver atrophy, spleen enlargement be hemorrhage, intestinal slight bleeding and hemorrhagic oophoritis etc. are feature, Pathogen identification is duck tembusu virus (clinic is commonly referred to as banzi virus), belong to flaviviridae Flavivirus carapuru virus class ntaya virus group, be single strand plus RNA virus。This virus is all pathogenic to the duck of various strains, duckling age in days of falling ill the earliest is that 7 ages in days, 20～40 ages in days and laying period are occurred frequently, this disease conventional anti-viral and antibacterial therapy unsatisfactory curative effect, death rate 5～15%, during secondary bacterial infection, death rate is higher, and recovering feed intake needs more than 15 days, and the rear dysplasia of commodity duck, laying ducks and laying rate recover poor, this disease is used for preventing without vaccine at present, causes tremendous economic to lose duck aquaculture。
Summary of the invention
For above the deficiencies in the prior art, the present invention proposes the method for preparation and use of the duck tembusu virus inactivated vaccine of a kind of preventing duck tembusu virus。
For reaching above-mentioned purpose, the technical scheme is that the inspection including kind of a poison, the preparation of antigen, the qualification of antigen, the preparation of vaccine and vaccine,
First step kind poison: duck tembusu virus separates falling ill duckling from 26 ages, identifies, is passaged to the acquisition of the 9th generation through susceptible duck embryo；
The preparation of second step antigen: the duck tembusu virus kind poison normal saline 10000 times dilution that will obtain, inoculates 11 age in days susceptible duck embryos, 0.1ml/ embryo through allantoic cavity, collect 48～120 hours dead duck embryo allantoic liquids of inoculation, steriling test is qualified, is antigen, in-40 DEG C of preservations；
In the 3rd step, viral level, pure property, specific immunogenic are identified, wherein in the qualification of viral level: antigen 10 times of serial dilutions of normal saline, take 10-4、10-5、10-6With 10-74 dilution factors inoculate 9 age in days susceptible duck embryos, and each dilution factor respectively inoculates 5 pieces, 0.1ml/ embryo, with hole of sealing with wax, standing hatching in 37.5 DEG C, duck embryo dead before 24 hours discards to be disregarded, collecting 24～168 hours dead duck embryos, calculating viral level by Reed-Muench method is 10-6.50ELD50/0.1ml。
Further, the preparation of vaccine: inactivation antigen adds transfer factor and duck leukocyte interleukin 2, makes the final concentration of 4mg/ml of transfer factor, and the final concentration of 5 μ g/ml of duck leukocyte interleukin 2, the duck tembusu virus content before inactivation is be more than or equal to 10-6.0ELD50/ 0.1ml, subpackage, 2-8 DEG C of preservation, it is duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine。
Beneficial effects of the present invention: the present invention prepares duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine; within 8 ages in days, duckling inoculation 0.3～0.5ml/ is only; commodity laying ducks and kind duck are only opening antenatal 15 days booster immunization 1.0ml/; the prevention & protection rate > 93% of whole breeding cycle; the duck Therapeutic Method routinely of fragmentary morbidity, cure rate significantly improves, convalescence shortens 5-7 days。Duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine is that clinical prevention duck tembusu virus disease provides effective means。
Detailed description of the invention
Embodiment
First step Zhong Du meat-type duck plant 26 age in days morbidity duckling separates and obtains duck tembusu virus, identify, be passaged to for the 9th generation through susceptible duck embryo and obtain。
Second step antigen prepares duck 10000 times of dilutions of tembusu virus kind poison normal saline, inoculates 11 age in days susceptible duck embryos, 0.1ml/ embryo through allantoic cavity, collects 48～120 hours dead duck embryo allantoic liquids of inoculation, and steriling test is qualified, is antigen, in-40 DEG C of preservations。Sampling simultaneously is used for identifying。
3rd step Antigen Identification
1 viral level
Antigen 10 times of serial dilutions of normal saline, take 10-4、10-5、10-6With 10-74 dilution factors inoculate 9 age in days susceptible duck embryos, and each dilution factor respectively inoculates 5 pieces, 0.1ml/ embryo, with hole of sealing with wax, standing hatching in 37.5 DEG C, duck embryo dead before 24 hours discards to be disregarded, collecting 24～168 hours dead duck embryos, calculating viral level by Reed-Muench method is 10-6.50ELD50/0.1ml。
2 pure property
It is qualified that antigen carries out antibacterial, mycoplasma and exogenous virus inspection according to existing " People's Republic of China's veterinary drug allusion quotation "。
3 specificitys
Antigen normal saline dilution is to 200ELD50/ 0.1ml, mixes with the anti-duck tembusu virus specific serum of equivalent, and with 1 hour in 37 DEG C of water-baths, allantoic cavity inoculates 9 age in days susceptible duck embryo 10 pieces, 0.1ml/ embryo；Set virus control 10 pieces simultaneously, inoculate the virus with condition process and mixed liquor of normal saline 0.1ml/ piece, above-mentioned duck embryo hole of sealing with wax, in 37 DEG C of stationary incubation, observe to 168 hours。Neutralization group duck embryo is all strong lives, and matched group duck embryo is all dead。Illustrate that antigen can be neutralized by anti-duck tembusu virus specific serum。
4 immunogenicities
4.1 antigens inactive
Antigen adds final concentration of 0.1% formaldehyde, and 37 DEG C inactivate 24 hours, period jolting 4 times, each 3 minutes。
4.2 inactivation inspections
4.2.1 aseptic according to existing " People's Republic of China's veterinary drug allusion quotation " inspection, should without bacterial growth。
4.2.2 safety verification inactivation antigen subcutaneously or intramuscularly injects 5 age in days duckling 10, and 1.0ml/ is only。Breeding observing 14 days, should occur without any locally and systemically untoward reaction caused by vaccine。
4.2.3 immunity inoculation 5 age in days health susceptible duckling 40, is divided into 2 groups, often group 20。The antigen 0.3ml that first group of neck dorsal sc injection inactivation inspection is qualified；Second group is matched group, is left intact, two groups of duckling isolated rearings。At latter 15 days of first group of immunity, above-mentioned 2 groups of duckling intramuscular injection 10000ELD50Duck tembusu virus, observe 10, add up each group of duckling morbidity death condition (duck clinical onset standard is: feed intake declines more than 20%, has loose bowels, and indivedual feet paralysis, stands or difficulty in walking, and cuing open inspection symptom is myocardial necrosis, and spleen is hemorrhage)。
4.2.4 first group of duckling of result is strong after counteracting toxic substances lives, without clinical onset symptom；Second group of duckling starts to show clinical onset symptom for 4 days after counteracting toxic substances, dead 1。Result illustrates that duck tembusu virus immunogenicity is good。
Prepared by the 4th step duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine
Inactivation antigen adds transfer factor and duck leukocyte interleukin 2, makes transfer factor (calculating by polypeptide) final concentration of 4mg/ml, the final concentration of 5 μ g/ml of duck leukocyte interleukin 2, duck tembusu virus content >=10 before inactivation-6.0ELD50/ 0.1ml, subpackage, 2-8 DEG C of preservation, it is duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine。
5th step vaccine test
1 steriling test vaccine is by existing " People's Republic of China's veterinary drug allusion quotation " inspection, all without bacterial growth。
5 age in days duckling 10 subcutaneously or intramuscularly injected by 2 safety examination vaccines, and 1.0ml/ is only。Breeding observing 14 days, should occur without any locally and systemically untoward reaction caused by vaccine。
Duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine immunizing dosage, duck age in days and protective rate relation
15 age in days duckling tests
1.1 method 5 age in days ducklings 40, are divided into 4 groups, often group 10, and 1-3 group is respectively through cervical region subcutaneous injection vaccine 0.2ml/, 0.3ml/, 0.4ml/；4 groups is matched group, is left intact。Latter 15 days of immunity, to all duckling intramuscular injection 10000ELD of 1-4 group50Duck tembusu virus, observe 10, add up each group of duckling morbidity death condition。
The duck tembusu virus infection clinical symptoms that 1.2 result 1 group ducklings have 2 to show difficulty in walking, have loose bowels, all the other are strong alive, and whole group is not dead。2 groups and 3 groups all strong alive。4 groups all show clinical onset symptom, dead 1, and cuing open inspection symptom is that hepatic atrophy, gollbladder dilation fill dark brown bile, spleen necrosis, intestinal slight bleeding。
28 age in days duckling tests
2.1 method 8 age in days ducklings 40, are divided into 4 groups, often group 10, and 1-3 group is respectively through cervical region subcutaneous injection vaccine 0.3ml/, 0.4ml/, 0.5ml/；4 groups is matched group, is left intact。Latter 15 days of immunity, to all duckling intramuscular injection 10000ELD of 1-4 group50Duck tembusu virus, observe 10, add up each group of duckling morbidity death condition。
2.2 results 1 group, 2 groups and 3 groups all strong work。4 groups of duck tembusu virus infection clinical symptoms all showing difficulty in walking, having loose bowels, dead。
330 week old laying ducks tests
3.1 method 30 week old lay eggs sheldrake (raiser locate buy, average daily ingestion amount about 160g/only, cluster laying rate 93%) 30, it is divided into 3 groups, often group 10, every hurdle area 5 square metres, raise scattered, adapting to environment after duck is marched into the arena, laying rate and feed intake start test when returning to normal。When 4 ducks all produce finished in the afternoon, 1-2 group is respectively through cervical region subcutaneous injection vaccine 1.0ml/ and 1.5ml/, and 3 groups is matched group, is left intact。Latter 15 days of immunity, to 1-3 group all ducks intramuscular injection duck tembusu virus 0.3ml, observe 10, add up each group of duck feed intake (every day feeds intake 2 times, every time by every 80g), laying rate and incidence, cut open inspection part duck, observe pathological changes。
After 3.2 result counteracting toxic substances 1 group and 2 groups of feed intakes normal, amount to 160g by every every day and feed intake and all can eat up；The mental status is active；Average egg production within the observation period 87% (grab duck during lower than laying rate 6% reason when jumpbogroup with counteracting toxic substances and injection causes stress be relevant)。3 groups show clinical onset symptom in 2 days after counteracting toxic substances, and within second day, feed intake compares decline 30%, laying rate 70% with time normal；Within 3rd day, feed intake compares decline 50%, laying rate 60% with time normal；Within 4th day, feed intake compares decline 56%, laying rate 20% with time normal；Terminating to the observation period, feed intake compares with time normal and decrease beyond 50%, and laying rate is not less than 20%, dead。Cuing open each 2 of 1 group and 2 groups ducks of inspection, follicular development is normal, and fallopian tube and internal organs have no pathological changes。3 groups of ducks 10 all cut open inspection, and follicle is hemorrhage, atrophy, and tubal wall has congested hemorrhage, and spleen is that mottled marble sample is downright bad, and pancreas has downright bad point, intestinal slight bleeding。
4 discuss
The prevention & protection test of 5 ages in days, 8 ages in days and 30 week old ducks is shown: duckling and laying ducks within 8 ages in days are inoculated 0.3-0.5ml/ by duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine respectively and 1.0-1.5ml/ prevention & protection rate only is 100%。
The test of protection antibody earliest time is produced after duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine immunity
1 method
5 age in days sheldrakes 120, are divided into 12 groups, often group 10, and respectively through intramuscular injection immune duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine 0.3ml/ only, 7-12 group is matched group to 1-6 group, is left intact。After immunity when 8,9,10,11,12,13 days, all duckling intramuscular inoculation 10000ELD to 1 and 7 group, 2 and 8 groups, 3 and 9 groups, 4 and 10 groups, 5 and 11 groups, 6 and 12 groups respectively50Duck tembusu virus。Observe 10 days after above-mentioned each group of virus inoculation, add up each group of duckling morbidity and death condition。
2 results
Each counteracting toxic substances matched group sickness rate 100%, mortality rate≤10%；The protection of immune vaccine group >=80% is that concrete outcome was in Table 1 latter 10 days of immunity。
Table 1 respectively organizes duckling sickness rate and protective rate
Packet 1 7 2 8 3 9 4 10 5 11 6 12
Sickness rate % 50 100 30 100 20 100 0 100 0 100 0 100
Mortality rate % 10 0 0 10 0 0 0 0 0 10 0 0
Protective rate % 50 0 70 0 80 0 100 0 100 0 100 0
Duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine immune duration test
1 method
5 age in days sheldrakes 100, are divided into 10 groups, often group 10, and respectively through intramuscular injection immune duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine 0.3ml/ only, 6-10 group is matched group to 1-5 group, is left intact。After immunity when 2,3,4,5,6 months, all duck intramuscular inoculation duck tembusu virus 0.3ml to 1 and 6 group, 2 and 7 groups, 3 and 8 groups, 4 and 9 groups, 5 and 10 groups respectively。Observe 10 days after above-mentioned each group of virus inoculation, add up each group of duck morbidity and death condition。
2 results
Counteracting toxic substances matched group duck sickness rate 100%, mortality rate≤20%, the duration of vaccine immunity group >=80% protective rate is 5 months, and the duration of 100% protection is 4 months, and concrete outcome is in Table 2。
Table 2 respectively organizes duck sickness rate and protective rate
Packet 1 6 2 7 3 8 4 9 5 10
Sickness rate % 0 100 0 100 0 100 20 100 40 100
Mortality rate % 0 10 0 0 0 20 0 10 0 0
Protective rate % 100 0 100 0 100 0 80 0 60 0
Duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine storage life test
1 method
It is taken at the 2-8 DEG C of duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine preserved, only 10 5 age in days sheldrake 0.3ml/ are inoculated respectively in time preserving 6,8,10,12 and 15 months, set 10 comparisons simultaneously, after vaccination 15 days respectively to immune group and matched group duck intramuscular inoculation duck tembusu virus 10000ELD50, observe 10 days after virus inoculation, add up each group of duck morbidity and death condition。
2 results
Matched group duckling sickness rate is 100%, mortality rate≤10%, preserves 6,8,10,12 months vaccination group ducklings 100% and protects, and the vaccination group preserving 15 months has 2 duckling morbidities, but not dead。So determining that of storage is: 2-8 DEG C of preservation, 12 months effect duration。
Duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine quality standard
This strain duck tembusu virus inoculates susceptible Duck embryo culture, and after results inoculation, the allantoic fluid of 48～120 hours dead duck embryos, inactivation, add transfer factor and duck leukocyte interleukin 2, make inactivated vaccine。For the prevention that duck tembusu virus is sick。
[character] this product is micro-brown to pink liquid, has microprecipitation at the bottom of being long placed in bottle。
[steriling test] detects by existing " People's Republic of China's veterinary drug allusion quotation ", should without bacterial growth。
[mycoplasma inspection] detects by existing " People's Republic of China's veterinary drug allusion quotation ", should grow without mycoplasma。
[exogenous virus inspection] detects by existing " People's Republic of China's veterinary drug allusion quotation ", should pollute without exogenous virus。
[safety verification] with 5 age in days susceptible health duckling 10, every subcutaneous injection this product 1.0ml, Continuous Observation 14 days, duckling should be all good for and be lived。
Containing duck tembusu virus and transfer factor, duck leukocyte interleukin 2 in [main component and content] vaccine。Duck tembusu virus content >=10 before inactivation-6.0ELD50/ 0.1ml, transfer factor (presses polypeptide to calculate) final concentration of 4mg/ml, the final concentration of 5 μ g/ml of duck leukocyte interleukin 2。
[residues of formaldehyde] detects by existing " People's Republic of China's veterinary drug allusion quotation ", should meet regulation。
[storage and effect duration] 2～8 DEG C of storages, effect duration is 12 months。
The operation instruction of duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine
[effect and purposes] is sick for preventing duck tembusu virus, and immune period is 4-5 month。
Containing duck tembusu virus and transfer factor, duck leukocyte interleukin 2 in [main component and content] vaccine。Duck tembusu virus content >=10 before inactivation-6.0ELD50/ 0.1ml, transfer factor (presses polypeptide to calculate) final concentration of 4mg/ml, the final concentration of 5 μ g/ml of duck leukocyte interleukin 2。
[character], for micro-brown to pink liquid, has microprecipitation at the bottom of being long placed in bottle。
[usage and consumption] is subcutaneously or intramuscularly injected。5-8 age in days duckling, every 0.3-0.5ml；Commodity laying ducks or plant duck and open antenatal 15 days, every 1.0ml, later every 4-5 month booster immunization 1 time, dosage is the same。
[points for attention]
1, this product is used for inoculating healthy duck。Body constitution is thin and weak, the person that suffers from other diseases, should not use。
2, vaccine should be first made to return to room temperature and fully shake up before using。
3, after vaccine unpacking, good the day it is finished。
4, this product can not be freezed。
5, the first-class apparatus of entry needle, sterilized with front need, 5% iodine disinfection should be embrocated in injection site。
6, within before and after laying period duck immune vaccine 3 days, in feedstuff or drinking-water, appropriate multidimensional is added, it is desirable to 1 hour after darkness starts immunity inoculation, gently grabs and put down gently, stress degree be minimized, in case impacting laying eggs。
[storage and effect duration] 8～12 DEG C of storages, effect duration is 12 months。
The foregoing is only presently preferred embodiments of the present invention, not in order to limit the present invention, all within the spirit and principles in the present invention, any amendment of making, equivalent replacement, improvement etc., should be included within protection scope of the present invention。

Claims (2)

1. the method for preparation and use of duck tembusu virus inactivated vaccine, it is characterised in that include the inspection of kind of a poison, the preparation of antigen, the qualification of antigen, the preparation of vaccine and vaccine,
Described first step kind poison: duck tembusu virus separates falling ill duckling from 26 ages, identifies, is passaged to the acquisition of the 9th generation through susceptible duck embryo；
The preparation of second step antigen: the duck tembusu virus kind poison normal saline 10000 times dilution that will obtain, inoculates 11 age in days susceptible duck embryos, 0.1ml/ embryo through allantoic cavity, collect 48～120 hours dead duck embryo allantoic liquids of inoculation, steriling test is qualified, is antigen, in-40 DEG C of preservations；
In the 3rd step, viral level, pure property, specific immunogenic are identified, wherein in the qualification of viral level: antigen 10 times of serial dilutions of normal saline, take 10-4、10-5、10-6With 10-74 dilution factors inoculate 9 age in days susceptible duck embryos, and each dilution factor respectively inoculates 5 pieces, 0.1ml/ embryo, with hole of sealing with wax, standing hatching in 37.5 DEG C, duck embryo dead before 24 hours discards to be disregarded, collecting 24～168 hours dead duck embryos, calculating viral level by Reed-Muench method is 10-6.50ELD50/0.1ml。
2. the method for preparation and use of duck tembusu virus inactivated vaccine according to claim 1, it is characterized in that: the preparation of described vaccine: inactivation antigen adds transfer factor and duck leukocyte interleukin 2, make the final concentration of 4mg/ml of transfer factor, the final concentration of 5 μ g/ml of duck leukocyte interleukin 2, the duck tembusu virus content before inactivation is be more than or equal to 10-6.0ELD50/ 0.1ml, subpackage, 2-8 DEG C of preservation, it is duck tembusu virus transfer factor-interleukin II adjuvant inactivated vaccine。
CN201610164617.6A 2016-03-22 2016-03-22 Preparation and use method of duck tembusu virus inactivated vaccine Pending CN105688203A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610164617.6A CN105688203A (en) 2016-03-22 2016-03-22 Preparation and use method of duck tembusu virus inactivated vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610164617.6A CN105688203A (en) 2016-03-22 2016-03-22 Preparation and use method of duck tembusu virus inactivated vaccine

Publications (1)

Publication Number Publication Date
CN105688203A true CN105688203A (en) 2016-06-22

Family

ID=56232424

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610164617.6A Pending CN105688203A (en) 2016-03-22 2016-03-22 Preparation and use method of duck tembusu virus inactivated vaccine

Country Status (1)

Country Link
CN (1) CN105688203A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110898218A (en) * 2019-12-30 2020-03-24 瑞普（保定）生物药业有限公司 Duck tembusu virus disease inactivated vaccine and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028421A (en) * 1989-05-25 1991-07-02 Embrex, Inc. Method of treating birds
EP2305304A1 (en) * 2008-04-28 2011-04-06 National University Corporation Hamamatsu University School of Medicine Immunopotentiating agent comprising ep1 agonist
CN102397539A (en) * 2011-11-25 2012-04-04 广东省农业科学院兽医研究所 Duckling flavivirus disease inactivated vaccine and preparation method thereof
CN102793923A (en) * 2012-08-29 2012-11-28 广州格雷特生物科技有限公司 Duck tembusu virus (DTMUV) disease immunotherapy preparation and preparation method thereof
CN102914647A (en) * 2012-05-29 2013-02-06 安徽农业大学 Method for detecting duck flavivirus antibody by using agar diffusion method
CN103143008A (en) * 2013-03-07 2013-06-12 齐鲁动物保健品有限公司 Duck tembusu virus living vaccine and preparation method thereof
CN103961693A (en) * 2013-01-24 2014-08-06 熊慧 Therapeutic vaccine for malignant tumors and composition thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028421A (en) * 1989-05-25 1991-07-02 Embrex, Inc. Method of treating birds
EP2305304A1 (en) * 2008-04-28 2011-04-06 National University Corporation Hamamatsu University School of Medicine Immunopotentiating agent comprising ep1 agonist
CN102397539A (en) * 2011-11-25 2012-04-04 广东省农业科学院兽医研究所 Duckling flavivirus disease inactivated vaccine and preparation method thereof
CN102914647A (en) * 2012-05-29 2013-02-06 安徽农业大学 Method for detecting duck flavivirus antibody by using agar diffusion method
CN102793923A (en) * 2012-08-29 2012-11-28 广州格雷特生物科技有限公司 Duck tembusu virus (DTMUV) disease immunotherapy preparation and preparation method thereof
CN103961693A (en) * 2013-01-24 2014-08-06 熊慧 Therapeutic vaccine for malignant tumors and composition thereof
CN103143008A (en) * 2013-03-07 2013-06-12 齐鲁动物保健品有限公司 Duck tembusu virus living vaccine and preparation method thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRAVOBLAS A等: ""Transfer factor acting as IFN-γ and IL-2 mRNA expression inductor in chicken vaccinated against avian influenza"", 《ARCHIVOS DE MEDICINA VETERINARIA》 *
姜平等: "《兽医生物制品学实验指导》", 28 February 2008, 北京.中国农业出版社 *
张勇等: "《动物疫情监测分析与疾病预防控制技术规范实施手册》", 28 February 2003, 内蒙古人民出版社 *
李振华等: ""鸭坦布苏病毒灭活油乳苗的制备及免疫效力测定"", 《中国预防兽医学报》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110898218A (en) * 2019-12-30 2020-03-24 瑞普（保定）生物药业有限公司 Duck tembusu virus disease inactivated vaccine and preparation method thereof
CN110898218B (en) * 2019-12-30 2023-10-10 瑞普（保定）生物药业有限公司 Duck tembusu virus inactivated vaccine and preparation method thereof

Similar Documents

Publication Publication Date Title
JP2571158B2 (en) Introduction of bacteria into eggs
CN104922663B (en) A kind of newcastle disease and H9 subtype avian influenza bigeminy vaccines
CN103495166B (en) Preparation method of complex live vaccine for porcine reproductive and respiratory syndrome
CN104946600B (en) A kind of H9 subtype avian influenza virus strain
CN105031638B (en) A kind of newcastle disease, bird flu and infectious bursa of Fabricius triple inactivated vaccine
CN103143008B (en) Duck tembusu virus living vaccine and preparation method thereof
CN111035756B (en) Porcine pseudorabies virus and porcine epidemic diarrhea virus combined inactivated vaccine and preparation method thereof
CN103495167B (en) A kind of preparation method of chicken infection bursal disease composite live vaccine
CN105106946B (en) A kind of cattle and sheep foot rot oil emulsion vaccine and preparation method thereof
CN103830724B (en) Muscovy duck parvovirus inactivation vaccine and application thereof
CN105920596B (en) Muscovy duck parvovirus disease and gosling plague bivalent vaccine
CN105688203A (en) Preparation and use method of duck tembusu virus inactivated vaccine
CN102965344B (en) Production of infectious bronchitis virus and vaccine from cell line
CN109207436A (en) One plant of 4 type aviadenovirus strain of I group and its application
CN102727881A (en) Highly pathogenic porcine reproductive and respiratory syndrome JXAl-R strain- porcine parvovirus disease bigeminal live vaccine and preparation method and application thereof
CN103495162B (en) Preparation method of porcine reproductive and respiratory syndrome compound inactivated vaccine
CN103143010B (en) Triad inactivated vaccine for newcastle disease and bird flu (H9 subtype) and escherichia coli disease and preparation method thereof
CN108743932A (en) A kind of inactivated vaccine preparation method for preventing duck reovirus
JPH0317807B2 (en)
CN111569059B (en) Antigen-antibody complex vaccine for poultry and preparation method thereof
CN108295053A (en) Application of the schizandrin in enhancing PEDV vaccine immune responses
CN107338227A (en) Bovine parainfluenza virus PBIV3 B strains and its application
CN105688204A (en) Meat duck parvovirus inactivated vaccine
CN103497933B (en) One application of strain H9N2 type bird flu strain on vaccine development
CN107982532B (en) Duck hepatitis A virus antigen-antibody complex vaccine and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160622